357 related articles for article (PubMed ID: 22721971)
1. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
Long SA; Rieck M; Sanda S; Bollyky JB; Samuels PL; Goland R; Ahmann A; Rabinovitch A; Aggarwal S; Phippard D; Turka LA; Ehlers MR; Bianchine PJ; Boyle KD; Adah SA; Bluestone JA; Buckner JH; Greenbaum CJ;
Diabetes; 2012 Sep; 61(9):2340-8. PubMed ID: 22721971
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice.
Manirarora JN; Wei CH
J Immunol; 2015 Dec; 195(11):5203-14. PubMed ID: 26482409
[TBL] [Abstract][Full Text] [Related]
3. β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice.
Johnson MC; Garland AL; Nicolson SC; Li C; Samulski RJ; Wang B; Tisch R
Diabetes; 2013 Nov; 62(11):3775-84. PubMed ID: 23884888
[TBL] [Abstract][Full Text] [Related]
4. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
5. CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.
Brenu EW; Bartley TJ; Wright CM; Hamilton-Williams EE
Immunol Cell Biol; 2017 Oct; 95(9):803-813. PubMed ID: 28611472
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin/GABA combination treatment ameliorates diabetes in NOD mice.
He S; Zhang Y; Wang D; Tao K; Zhang S; Wei L; Chen Q
Mol Immunol; 2016 May; 73():130-7. PubMed ID: 27082922
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice.
Rabinovitch A; Suarez-Pinzon WL; Shapiro AM; Rajotte RV; Power R
Diabetes; 2002 Mar; 51(3):638-45. PubMed ID: 11872661
[TBL] [Abstract][Full Text] [Related]
9. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
Dong S; Hiam-Galvez KJ; Mowery CT; Herold KC; Gitelman SE; Esensten JH; Liu W; Lares AP; Leinbach AS; Lee M; Nguyen V; Tamaki SJ; Tamaki W; Tamaki CM; Mehdizadeh M; Putnam AL; Spitzer MH; Ye CJ; Tang Q; Bluestone JA
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34324441
[TBL] [Abstract][Full Text] [Related]
10. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
11. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes.
Baeyens A; Pérol L; Fourcade G; Cagnard N; Carpentier W; Woytschak J; Boyman O; Hartemann A; Piaggio E
Diabetes; 2013 Sep; 62(9):3120-31. PubMed ID: 23670972
[TBL] [Abstract][Full Text] [Related]
12. Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience.
Ehlers MR; Nepom GT
Rev Diabet Stud; 2012; 9(4):359-71. PubMed ID: 23804273
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in type 1 diabetes: a shorter but more winding road?
Bonifacio E
Diabetes; 2012 Sep; 61(9):2214-5. PubMed ID: 22923646
[No Abstract] [Full Text] [Related]
14. Altered homeostasis and development of regulatory T cell subsets represent an IL-2R-dependent risk for diabetes in NOD mice.
Dwyer CJ; Bayer AL; Fotino C; Yu L; Cabello-Kindelan C; Ward NC; Toomer KH; Chen Z; Malek TR
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259102
[TBL] [Abstract][Full Text] [Related]
15. Roles of cytokines in the pathogenesis and therapy of type 1 diabetes.
Rabinovitch A; Suarez-Pinzon WL
Cell Biochem Biophys; 2007; 48(2-3):159-63. PubMed ID: 17709885
[TBL] [Abstract][Full Text] [Related]
16. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.
Yu A; Snowhite I; Vendrame F; Rosenzwajg M; Klatzmann D; Pugliese A; Malek TR
Diabetes; 2015 Jun; 64(6):2172-83. PubMed ID: 25576057
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of regulatory T cells in type 1 diabetes.
Marek-Trzonkowska N; Myśliwec M; Siebert J; Trzonkowski P
Pediatr Diabetes; 2013 Aug; 14(5):322-32. PubMed ID: 23627860
[TBL] [Abstract][Full Text] [Related]
18. CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms.
Yuan X; Dong Y; Tsurushita N; Tso JY; Fu W
JCI Insight; 2018 Jan; 3(2):. PubMed ID: 29367461
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
J Autoimmun; 2023 Nov; 140():103125. PubMed ID: 37844543
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD44 augments the efficacy of Tregs in autoimmune diabetes.
Li CR; Mueller EE; Bradley LM
Immunol Lett; 2015 Feb; 163(2):199-205. PubMed ID: 25447401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
